These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22101805)

  • 1. Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism.
    Hori K
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):109-22. PubMed ID: 22101805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface.
    Hori K; Akita H; Nonaka H; Sumiyoshi A; Taki Y
    Cancer Sci; 2014 Sep; 105(9):1196-204. PubMed ID: 24981848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor environment changed by combretastatin derivative (Cderiv) pretreatment that leads to effective tumor targeting, MRI studies, and antitumor activity of polymeric micelle carrier systems.
    Shiraishi K; Harada Y; Kawano K; Maitani Y; Hori K; Yanagihara K; Takigahira M; Yokoyama M
    Pharm Res; 2012 Jan; 29(1):178-86. PubMed ID: 21789726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
    Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
    J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors.
    Hori K; Nishihara M; Shiraishi K; Yokoyama M
    J Pharm Sci; 2010 Jun; 99(6):2914-25. PubMed ID: 20039393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
    Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
    J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700).
    Hori K
    Chemotherapy; 2005 Oct; 51(6):357-60. PubMed ID: 16227690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combretastatin-based compounds with therapeutic characteristics: a patent review.
    Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
    Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
    [No Abstract]   [Full Text] [Related]  

  • 9. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.
    Hori K; Saito S
    Br J Cancer; 2003 Oct; 89(7):1334-44. PubMed ID: 14520469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
    Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combretastatin A4 phosphate].
    Verdier-Pinard P; Lansiaux A; Bailly C
    Bull Cancer; 2001 Mar; 88(3):235-9. PubMed ID: 11313199
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700).
    Hori K; Saito S
    Br J Cancer; 2004 Jan; 90(2):549-53. PubMed ID: 14735207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4.
    Aleksandrzak K; McGown AT; Hadfield JA
    Anticancer Drugs; 1998 Jul; 9(6):545-50. PubMed ID: 9877243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biology of the combretastatins as tumour vascular targeting agents.
    Tozer GM; Kanthou C; Parkins CS; Hill SA
    Int J Exp Pathol; 2002 Feb; 83(1):21-38. PubMed ID: 12059907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combretastatin analogues in cancer biology: A prospective view.
    Sherbet GV
    J Cell Biochem; 2020 Mar; 121(3):2127-2138. PubMed ID: 31774211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
    Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
    Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
    Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
    Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of pironetin analogue/combretastatin A-4 hybrids containing a 1,2,3-triazole ring and evaluation of their cytotoxic activity.
    Vilanova C; Torijano-Gutiérrez S; Díaz-Oltra S; Murga J; Falomir E; Carda M; Alberto Marco J
    Eur J Med Chem; 2014 Nov; 87():125-30. PubMed ID: 25240870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumour vasculature: the development of combretastatin A4.
    Griggs J; Metcalfe JC; Hesketh R
    Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.